Biotechnology

Aprea Therapeutics

Aprea Therapeutics released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 1.848K (forecast USD 0), actual EPS USD -0.4664 (forecast USD -0.34)

Aprea Therapeutics released FY2025 9 Months Earnings on November 12 (EST), actual revenue USD 282.42K, actual EPS USD -1.6549

Introduction of Aprea Therapeutics

Analyst Recommends Buy Rating for Aprea Therapeutics

Aprea Therapeutics released FY2025 Semi-Annual earnings on August 12 (EST), actual revenue USD 280.57 K, actual EPS USD -1.1875

Aprea Therapeutics released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 118.11 K (forecast USD 0), actual EPS USD -0.5324 (forecast USD -0.745)

Aprea Reports Early Clinical Data for APR-1051 in HPV-Positive HNSCC

Aprea Therapeutics Holds Annual Shareholder Meeting to Elect Directors

Aprea Therapeutics released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 162.46K (forecast USD 0), actual EPS USD -0.6561 (forecast USD -0.58)

CEO of Aprea Therapeutics Increases Stock Holdings

Aprea Therapeutics released FY2024 annual earnings on March 25 (EST), actual revenue $1.503M (forecast $1.339M), actual EPS -$2.3518 (forecast -$2.5466)

Aprea Therapeutics released FY2024 Q4 earnings on March 25 (EST), actual revenue 205.82 K USD (forecast 150 K USD), actual EPS -0.4861 USD (forecast -0.6866 USD)

Aprea Therapeutics Inc Reports Quarterly Financial Performance with 1371.4% Revenue Surge

Aprea Therapeutics Inc Expects Loss of $0.69 per Share with Revenue Growth of 1,090.5%

Aprea Therapeutics Announces Progress in Intellectual Property in Cancer Treatment

Aprea Therapeutics released FY2024 Q3 earnings on November 7, 2024 (EST), with actual revenue of 354,621 (forecast 150K) and actual EPS of -0.637 (forecast -0.8)

Aprea Therapeutics released FY2024 9 Months Earnings on November 7, 2024 (EST), with actual revenue of 1,296,764 USD and EPS of -1.8908

Aprea Therapeutics Announces Latest Developments in Precision Oncology

Aprea Therapeutics Announces Company Update Presentation

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

ADMA生物制藥

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel制藥

OpGen

福泰制藥

再生元制藥

Argenx

阿里拉姆制藥

百濟神州

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap